Icon Group in Australia Selects Varian Advanced Radiotherapy Equipment | Varian

{ "pageType": "news-article", "title": "Icon Group in Australia Selects Varian Advanced Radiotherapy Equipment", "articleDate": "2016/06/16", "introText": "", "category": "Oncology" }

Icon Group in Australia Selects Varian Advanced Radiotherapy Equipment

PALO ALTO, Calif., June 16, 2016 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR), today announced it has been selected by the Icon Group to provide 10 TrueBeam® medical linear accelerators for cancer centers Icon operates across Australia. Varian will install the TrueBeam systems in the Icon centers over the next two years and continue to service them under a multi-year agreement.

Varian's TrueBeam family of medical linear accelerators incorporate numerous technical innovations that dynamically synchronize imaging, patient positioning, motion management, and treatment delivery during a radiotherapy or radiosurgery procedure. In addition to the TrueBeam systems, Icon is also ordering Varian's software suite including the Eclipse™ treatment planning system and ARIA® oncology information management system.

"This agreement is reflective of the strong relationship between our two companies and the high quality cancer treatment equipment and service Varian delivers," said Mark Middleton, CEO of Icon Group. "These ten new TrueBeam systems mean we can provide advanced cancer treatment to more patients across Australia, in addition to the five systems ordered last year and the nine currently in place. Varian technology and services make it possible to deliver quality care rapidly and efficiently so that we can serve more patients."

"We are honored Icon selected Varian systems and software to increase its ability to deliver precise treatments to a greater number of cancer patients across Australia," said Kolleen Kennedy, president of Varian's Oncology Systems business. "We will continue to work closely with Icon on the deployment of these systems and increasing patient access to high quality cancer care."

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging.  The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, cables and connectors as well as image processing software and workstations for use in medical and industrial settings, as well as for security and non-destructive testing.  Varian Medical Systems employs approximately 7,500 people who are located at manufacturing sites in North America, Europe, and China and sales and support offices around the world.  For more information, visit http://www.varian.com or follow us on Twitter.

About Icon Group

Icon Group is backed by Quadrant Private Equity. The Group encompasses Icon Cancer Care: Australia's largest private day oncology provider with seven sites across Queensland and South Australia; Radiation Oncology Centres (ROC): Australia's fastest growing radiation oncology provider with 10 sites across Queensland and New South Wales and a further six in development; Epic Pharmacy – an innovative network of hospital, oncology and aged care pharmacies; and Slade Health: one of Australia's largest chemotherapy compounders with TGA-approved manufacturing sites across the eastern seaboard.

Forward Looking Statement

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues or other financial performance; the ability of the company's technology and products to treat cancer; customer delivery schedules; and any statements using the terms "will" or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the demand for the company's products; the company's ability to develop, commercialize, and deploy new and existing products; the impact of competitive products and pricing; the effect of global economic conditions;  the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Press Contact

Mark Plungy
Varian Medical Systems
+1 (650) 424-5630


SOURCE Varian Medical Systems